Recorded fact · drug.label_indication
drug.label_indication for regorafenib|gastrointestinal-stromal-tumor
One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact e85ccbd8 resolves to.
The record
| Fact id | e85ccbd88cddab1cf244c00d |
|---|---|
| Entity | drug: regorafenib|gastrointestinal-stromal-tumor |
| Field | drug.label_indication |
| Source | api.fda.gov |
| Read on | 2026-11-10T19:02:47.536Z |
| Source version | openfda-label-20260209 |
| Method | extract |
| Verification | verified |
| Licence | CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels |
| Edition | 2026-11, Merkle root 006ab9a329709cbe... |
The verifying quote
Locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.
Shown with dashes as hyphens. SHA-256 of the exact stored quote: 0988f7775edf78f9ccfb347f1af158f62c6896dfa707e7964e4c9d864193b069.
The value
{
"ingredient": "Regorafenib",
"conditionId": "gastrointestinal-stromal-tumor",
"conditionName": "Gastrointestinal stromal tumor",
"matchedAlias": "gastrointestinal stromal tumor",
"context": "indication",
"brand": "Stivarga",
"identifiedVia": "generic_name",
"extractor": 5,
"labelSetId": "824f19c9-0546-4a8a-8d8f-c4055c04f7c7",
"labelEffectiveTime": "20260209",
"labelsRead": 1,
"labelsNaming": 1,
"registryEditionRoot": "1b44e76f5da1a417",
"meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
}SHA-256 of the exact stored value: 43bfd9197f07b4a7383a9d114212251375ff751f35f587834865c3e1f5a1f3ef.
This fact as data (JSON) · Check an answer against its receipt · Licence
Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.